Poseida Therapeutics Inc
NASDAQ:PSTX

Watchlist Manager
Poseida Therapeutics Inc Logo
Poseida Therapeutics Inc
NASDAQ:PSTX
Watchlist
Price: 2.73 USD 0.74% Market Closed
Market Cap: 266.1m USD
Have any thoughts about
Poseida Therapeutics Inc?
Write Note

Poseida Therapeutics Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Poseida Therapeutics Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Poseida Therapeutics Inc
NASDAQ:PSTX
Short-Term Investments
$167.7m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Short-Term Investments
$28m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Short-Term Investments
$1.3B
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Short-Term Investments
$7.8B
CAGR 3-Years
49%
CAGR 5-Years
39%
CAGR 10-Years
35%
No Stocks Found

Poseida Therapeutics Inc
Glance View

Market Cap
265.9m USD
Industry
Biotechnology

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 263 full-time employees. The company went IPO on 2020-07-10. The firm is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. The company is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The firm's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).

PSTX Intrinsic Value
0.87 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Poseida Therapeutics Inc's Short-Term Investments?
Short-Term Investments
167.7m USD

Based on the financial report for Dec 31, 2023, Poseida Therapeutics Inc's Short-Term Investments amounts to 167.7m USD.

What is Poseida Therapeutics Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 3Y
-9%

Over the last year, the Short-Term Investments growth was -17%. The average annual Short-Term Investments growth rates for Poseida Therapeutics Inc have been -9% over the past three years .

Back to Top